ABSTRACT
Infections with EBV and CMV have previously been implicated in influencing 98 allergic disorders but their precise role remains controversial. Some studies have suggested 99 allergy protective 8, 9 or -promoting 10-12 effects, while others could not demonstrate a clear role 100
for EBV or CMV in the pathogenesis of allergic disorders 13, 14 . A previous study from our 101 group showed an inverse relation between EBV infection and IgE-sensitization in a cohort of 102
Swedish two-year old infants 9 . We also observed that seropositivity with CMV in the absence 103 of EBV tended to associate with a higher risk of IgE-sensitization. This suggests that infection 104 with EBV during the two first years of life may protect from allergy. We have also recently 105 was determined in 195 (three additional subjects) out of 219 five-year olds. The study was 135 approved by the Human Ethics Committee at Huddinge University Hospital, Stockholm, and 136 the parents provided informed consent. 137
138

Skin Prick Testing and determination of circulating allergen-specific IgE 139
The children underwent SPT against food and inhalant allergens, which were performed 140 according to the manufacturer's recommendation (ALK, Copenhagen, Denmark). The SPT, at 141 two and five years of age, included food allergens: egg white (Soluprick weight to volume 142 ratio 1/100); cod (Soluprick 1/20); peanut, (Soluprick 1/20); cow's milk (3% fat, standard 143 milk) and soybean protein (Soja Semp Semper AB, Stockholm, Sweden). SPT was also 144 performed for inhalant allergens: cat; dog; Dermatophagoides farinae; birch and timothy 145 (Soluprick 10 HEP). In addition to aforementioned allergens, subjects were also tested for 146 rabbit at the age of five (Soluprick 10 HEP). The SPT was considered positive if the wheal 147 diameter was ≥ 3 mm after 15 minutes. Histamine chloride (10 mg/ml) and the allergen 148 diluent served as positive and negative control respectively. The children were serologically 149 tested for IgE against the same allergens as those used for SPT, all performed with 150 both two-and five-years of age. Among these, six children were excluded since the results of 160 the EBV analyses were indeterminate despite repeated examination or due to insufficiency of 161 plasma volumes for performance of additional analyses. The remaining 219 subjects were 162 classified according to presence or absence of IgE-sensitization as follows: non-sensitized 163 (neither IgE-sensitized at two-nor at five-years of age), n=129 (59%); transiently sensitized 164 (IgE-sensitized at two-but not at five-years of age), n=7 (3%); persistently sensitized (IgE-165 sensitized at both two-and five-years of age), n=48 (22%) and late sensitized (IgE-sensitized 166 at five-but not at two-years of age), n=35 (16%, table 1). 167
168
Statistical methods 169
Odds ratio (OR) estimates and corresponding 95% confidence intervals (95% CI) for 170 development of IgE-sensitization were obtained by logistic regression. Data were adjusted for 171 the following background variables: sex, parental allergy (none, maternal or both parents), 172 maternal age, duration of breast-feeding, furred pets, month of birth, older siblings and 173 parental smoking by multiple logistic regression analysis. Mann-Whitney U-test was used to 174 assess differences in IgE-levels between sample groups. Fisher's exact test was applied to 175 evaluate differences between the transiently sensitized and non-sensitized group and to test 176 differences in susceptibility to EBV or CMV infection between sensitized and non-sensitized 177 subjects. Statistical analyses were performed at the Division of Mathematical Statistics, 178
Stockholm University. P-values below 0.05 were considered statistically significant. 179
IgE-sensitization among five-year olds 182
Among the 219 five-year olds, 83 (38%) were classified as IgE-sensitized. In the group of 183 persistently IgE-sensitized subjects (n=48), 37 (77%) were SPT positive while 46 children 184 (96%) had a positive test for circulating IgE against one or more of the selected allergens. 185
Corresponding data for the late-sensitized group (n=35), was 21 (60%) for SPT and 34 186 children (97%) for circulating specific IgE. The group of persistently sensitized children had 187 higher levels of allergen-specific IgE compared with late-sensitized subjects (p<0.01, Fig 1) . 188 No significant differences were seen between non-sensitized, persistently sensitized and late 189 sensitized children with regard to maternal age, birth weight, gestation week, maternal or 190 paternal smoking (data not shown). We observed, however, that IgE-sensitized children were 191 significantly more likely to have two allergic parents and that the group of persistently 192 sensitized children was more likely to be born during the winter than late sensitized and non-193 sensitized children. Further, delivery by caesarean section was more common among late 194 sensitized children (Table 1 We examined the frequency of EBV and CMV seropositivity in relation to IgE-sensitization 209 during infancy and childhood ( Table 2 ). The transiently sensitized group was excluded from 210 these analyses since it contained too few subjects (n=7) for a reliable statistical outcome. As 211 the number of subjects with determined serostatus differed between the two and five year 212 olds, table 2 was divided in section A; where relation between serostatus at age two and 213 persistent IgE-sensitization was evaluated, and section B; where serostatus at two or between 214 two and five years of age was related to late IgE-sensitization. We found that the five-year 215 old children who were EBV seropositive at two-years of age were at a decreased risk of being 216 persistently IgE-sensitized (adjusted odds ratio, OR adj, 0.34; 95% CI 0.12-0.94). This 217 association was not observed for CMV infection, which rather tended to be associated with an 218 increased risk (OR adj 1.66; 95% CI 0.84-3.31). In sharp contrast to EBV-infection before the 219 age of two, EBV seropositivity acquired between the ages of two and five was related to a 220 significantly higher risk of having developed IgE-sensitization at five-years of age (late IgE-221 sensitized, OR adj 4.64; 95% CI 1.57-13.69). No such association was observed for CMV 222 infection. The frequency of early EBV infection, i.e. seropositivity at two-years of age, did 223 not differ between late sensitized and non-sensitized five-year old children (OR adj 1.36; 95% 224 CI 0.47-3.92), which suggests that early infection with EBV does not protect against late IgE-225 sensitization. No protective effect was observed when persistently and late-sensitized subjects 226 were regrouped into one group and compared with the non-sensitized children (data not 227 shown). 228 regrouped the transiently sensitized and the persistently sensitized subjects into one group, 230
given that the children in both groups were IgE-sensitized at two-years of age. However, we 231 observed no noteworthy changes in the results when these children were grouped together 232 (OR adj 0.37; 95% CI 0.14-0.95 for transient plus persistent, not displayed in table) . 233
234
Relation between IgE-sensitization and susceptibility to EBV and CMV 235
We also addressed whether susceptibility to EBV or CMV is altered in IgE-sensitized 236 subjects. To this end, we excluded two-year olds who were seropositive for both EBV and 237 CMV, divided the remaining children into IgE-sensitized or non-sensitized and analyzed the 238 frequency of EBV and/or CMV seropositivity at five-years of age. There were no differences 239 in the proportion of subjects who seroconverted for EBV and/or CMV between the IgE-240 sensitized and non-sensitized group (Table 3 ), suggesting that acquisition of EBV and CMV 241 is not influenced by the infant's allergic status. 242
243
DISCUSSION
244
This study demonstrates that acquisition of EBV infection during early-life associates with a 245 reduced risk of persistent IgE-sensitization. This effect seems to be limited to a relatively 246 short time period during infancy, as infection with EBV after two-years of age relates to a 247 significantly higher risk of IgE-sensitization. However, EBV infection during infancy does 248 not confer protection against IgE-sensitization later in childhood. Interestingly, we observed 249 markedly higher allergen-specific IgE levels among persistently IgE-sensitized children than 250 among late sensitized children. This could set the stage for the development of atopic 251 phenotypes as it has been shown that persistent atopic sensitization with an early-onset 252 confers a higher risk for developing allergic asthma/wheezing later in life than late-onset 253 sensitization 20, 21 . 254
The concept of an "early window of opportunity" for protection against allergy 255 underscores the importance of exposure to pathogenic and non-pathogenic microorganisms 256 during the earliest periods of life for proper shaping of the immune system away from the 257 allergic phenotype 22 . Our data indicates that early-life EBV infection may contribute to this 258 immunomodulation and suggests that examination of defined age groups might overcome 259 contradictions between previous reports on EBV's relation to allergy. Calvani et al observed 260
that EBV infection during early childhood (especially <29 months) was related to protection 261 against atopy, as opposed to primary EBV-infection in older children 8 . In the study of 262
Sidorchuck et al, where no association could be demonstrated, 4-year old children were 263 investigated 13 , which in relation to our findings would be children both exposed to the 264 protective effect before two years and the aggravating effect thereafter. In studies where EBV 265 infection has been pointed out as a risk factor in atopy the investigated subjects were either 266 between five and 18-years old 10 It has been suggested that infants predisposed to allergies require a strong and 287 adequate immune stimulation at a very young age to overcome maturational deficiencies in 288 their immune system 24 . EBV, presumably in addition to other suggested microbial candidates 289 such as intestinal bacteria 25 , might represent one such stimulatory agent. Indeed, the majority 290 of children below 3-years of age are infected with EBV in developing countries 5 where the 291 occurrence of allergic disorders is uncommon 26 . However, the asthma prevalence in those 292 countries seems to rise now and increased industrialization has been proposed as a causing 293 factor 27 . Other viral agents have been discussed in relation to allergy, both as being protective 294 and as risk factors 28 . For instance, Hepatitis A has been shown to inversely correlate to the 295 prevalence of atopic diseases and Measels has been suggested to protect against IgE 296 sensitization but the results are contradictory 29 . In the case of respiratory syncytial virus 297 (RSV) infection, it appears that infants who require hospital care have a higher prevalence of 298 asthma and allergy compared to children without severe symptoms 30 . Our data here does not 299 support a risk modulation by CMV, which is in agreement with previous observations 9, 13 . 300 rather the type of infecting agent might be of importance in the modulation of the risk to 302 become IgE-sensitized. 303
The quality of innate and acquired responses in the two-year olds from this 304 cohort has been previously reported. Interestingly, we found that EBV seropositivity 305 associates with a lower monocyte-dependent IFN-γ release by NK cells 31 whereas T-cell 306 cytokine responses tend to be enhanced 15 . Therefore, an alternative, or additive, mechanism 307 behind the protective effect of early EBV infection could be that attenuated innate responses 308 facilitate a general boost of adaptive immunity. 309
We should acknowledge some study limitations. In agreement with other 310 reports 20,21 , the subjects in our study were classified into four sensitization groups, where the 311 transiently sensitized included very few subjects. The exclusion of the transiently IgE-312 sensitized group from the analyses of EBV's relation to protection against persistent IgE-313 sensization could have biased our results, but since regrouping of the transient group with the 314 persistent did not alter the outcome of our findings this is unlikely. Further, the 315 seroprevalence of EBV (38%) among five-year olds in this cohort was lower than described 316 for a previous cohort of 2561 Swedish children from the whole Stockholm region, where 53% 317 were EBV seropositive at the age of 4 13 . Our smaller cohort size and that all participants were 318 recruited from a limited part of Stockholm might be possible explanations for the 319 discrepancy. Since two assays for EBV seropositivity were combined in our study, we believe 320 that our evaluation of seropositivity is highly accurate. It should be stressed that the purpose 321 of this study was not to examine EBV seroprevalence, but the relation between infection with 322 EBV and CMV and IgE-sensitization. 
